

Number 645 • November 2016

Temporary benefit added to the Alberta Drug Benefit List (ADBL)

Due to the unavailability of Teva-Spironolactone 25 mg Tablet (DIN 00613215) manufactured by Teva Canada Limited, Aldactone 25 mg Tablet (DIN 00028606) manufactured by Pfizer Canada Inc. will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of October 31, 2016, all claims for Aldactone 25 mg Tablet (DIN 00028606) will be adjudicated to the price published in the most recent Alberta Blue Cross Drug Price List (ABCDPL) until further notice. The ABCDPL is available online at https://www.ab.bluecross.ca/providers/pharmacy-home.html.

If this situation continues to be a long-term matter, then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics, and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit https://www.ab.bluecross.ca/providers/pharmacy-home.php**



